ELTX Elicio Therapeutics Forecast, Technical & Fundamental Analysis
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers... Show more
ELTX is expected to report earnings to -64 cents per share on August 07
Q2'26
Est.
$-0.65
Q1'26
Missed
by $0.04
Q4'25
Beat
by $0.19
Q3'25
Beat
by $0.08
Q2'25
Beat
by $0.01
The last earnings report on May 11 showed earnings per share of -64 cents, missing the estimate of -61 cents. With 127.12K shares outstanding, the current market capitalization sits at 271.02M.
A.I.dvisor indicates that over the last year, ELTX has been loosely correlated with PRME. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ELTX jumps, then PRME could also see price increases.
ELTX in upward trend: 10-day moving average crossed above 50-day moving average on June 04, 2026
The 10-day moving average for ELTX crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 29, 2026. You may want to consider a long position or call options on ELTX as a result. In of 117 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ELTX just turned positive on May 27, 2026. Looking at past instances where ELTX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
ELTX moved above its 50-day moving average on May 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ELTX advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ELTX broke above its upper Bollinger Band on June 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ELTX entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ELTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (133.333) is normal, around the industry mean (19.567). P/E Ratio (5.957) is within average values for comparable stocks, (35.932). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.687). ELTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (355.865).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
